Syndax Pharmaceuticals Inc Stock News

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Citi's Biopharma Back to School Conference September 2, 2025 4:45 PM EDT Company Participants Keith Goldan - CFO, Treasurer & Chief Accounting Officer Steven Closter - Chief Commercial Officer Nicholas Botwood - Head of Research & Development and Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division P...

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

Shares of Syndax Pharmaceuticals are still down 45% over the past three years. The Q2 report was encouraging on multiple fronts with a strong start for the Revuforj launch in KMT2A AML and Niktimvo launch in chronic GVHD. Incyte is the ideal partner for GVHD, being highly familiar with this space and the 50/50 split in the US provides a significant downside cushion to investors.

NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2025 the Company granted inducement awards to purchase up to 48,600 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four ye...

Syndax Pharmaceuticals just delivered strong second quarter results, beating expectations, and management also increased its long-term market opportunity projections. Both Revuforj and Niktimvo are driving rapid revenue growth, with management now targeting $10 billion in peak sales for both drugs combined. Analysts remain bullish and profitability could arrive by FY 2028, a year earlier than c...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Keith Alan Goldan - CFO, Treasurer & Chief Accounting Officer Michael A. Metzger - CEO & Director Nicholas Botwood - Head of Research and Development and Chief Medical Officer Sharon Klahre Peter Richard Lawson - Vice President of Investor Relations & Communications Steven...

Syndax (SNDX) Q2 Revenue Jumps 986%

– $28.6 million of Revuforj ® (revumenib) net revenue, representing 43% growth over 1Q25 –